Actuate to initiate Phase 1/2 clinical trial for elraglusib tablet in 2026.

Actuate Therapeutics plans to initiate a Phase 1/2 clinical program for elraglusib, an oral tablet for advanced cancer treatment, in 2H 2026. The program will focus on refractory melanoma and other solid tumor and hematologic cancers. The Phase 1 portion will determine the recommended dose and safety profile, while the Phase 2 portion will evaluate the efficacy of elraglusib in specific indications. The program builds on early clinical evidence of monotherapy activity in CPI-refractory metastatic melanoma.